سعر اندوفوريل 100 مجم 30 كبسولة 2022

Capsules containing naftidrofuryl 100 mg (Al Andalous Pharmaceutical Industries), a peripheral vasodilator; 30 capsules per pack.

• Peripheral vascular disorders (intermittent claudication, night cramps, rest pain, incipient gangrene, trophic ulcers, Raynaud's syndrome, diabetic arteriopathy, acrocyanosis)Population: AdultsAccord-UK Ltd (Accord Products Database; MHRA-authorised SmPC)

• Uncommon: diarrhoea, nausea, vomiting, epigastric pain, skin rash. Rare: liver damage. Very rare: calcium oxalate kidney stones. Frequency not known: oesophagitis when taken without liquid before bed.International label, same formulation · Accord-UK Ltd (Accord Products Database; MHRA-authorised SmPC)

• Hypersensitivity to naftidrofuryl oxalate or any excipient.International label, same formulation · Accord-UK Ltd (Accord Products Database; MHRA-authorised SmPC)
• History of hyperoxaluria or recurrent calcium-containing kidney stones.International label, same formulation · Accord-UK Ltd (Accord Products Database; MHRA-authorised SmPC)

• May promote calcium oxalate kidney stones (oxalate content 19 mg per 100 mg); maintain adequate fluid intake and diuresis.International label, same formulation · Accord-UK Ltd (Accord Products Database; MHRA-authorised SmPC)
• Always take with sufficient water; taking without liquid before bed may cause local oesophagitis.International label, same formulation · Accord-UK Ltd (Accord Products Database; MHRA-authorised SmPC)
• Cases of liver damage reported; discontinue if symptoms suggest liver damage.International label, same formulation · Accord-UK Ltd (Accord Products Database; MHRA-authorised SmPC)

• In the absence of relevant clinical data, use during pregnancy is not advisable.International label, same formulation · Accord-UK Ltd (Accord Products Database; MHRA-authorised SmPC)
• Should not be used by breast-feeding women (excretion in milk unknown).International label, same formulation · Accord-UK Ltd (Accord Products Database; MHRA-authorised SmPC)

• Naftidrofuryl (salt form not stated by the Egyptian source): Direct effect on intracellular metabolism: increases ATP and decreases lactic acid levels under ischaemic conditions (enhanced cellular oxidative capacity); also a spasmolytic agent (UK SmPC).